Abstract: An osmotic pump controlled release tablet and the preparation method thereof are disclosed. The osmotic pump controlled release tablet is composed of tablet core, semipermeable membrane and optional film coating. The material of said semipermeable membrane is composed of ethyl cellulose and povidone in the ratio of 1:1˜1:4 by weight. Said tablet core comprises drug containing layer and push layer. The osmotic pump controlled release tablet also characterizes in that; (1) the angle ?1 formed by the outer curved surface of the drug containing layer and the lateral surface is 120°-180°; and/or (2) the ratio of L1 to r is 0.27-1.0, wherein L1 is the vertical distance from the central vertex of the outer curved surface of the drug containing layer to the plane formed by the intersection line between the outer curved surface of the drug containing layer and the lateral surface, and r is the radius of the tablet core.

Abstract: An osmotic pump controlled release tablet and the preparation method thereof are disclosed. The osmotic pump controlled release tablet is composed of tablet core, semipermeable membrane and optional film coating. The material of said semipermeable membrane is composed of ethyl cellulose and povidone in the ratio of 1:1˜1:4 by weight. Said tablet core comprises drug containing layer and push layer. The osmotic pump controlled release tablet also characterizes in that; (1) the angle ?1 formed by the outer curved surface of the drug containing layer and the lateral surface is 120°-180°; and/or (2) the ratio of L1 to r is 0.27-1.0, wherein L1 is the vertical distance from the central vertex of the outer curved surface of the drug containing layer to the plane formed by the intersection line between the outer curved surface of the drug containing layer and the lateral surface, and r is the radius of the tablet core.

Abstract: A gastroretentive drug delivery system is provided. Said system comprises a hollow vesicle and a drug-containing layer which surrounds the hollow vesicle. Said hollow vesicle preferably has a single chamber structure. The size in maximal diameter direction of said hollow vesicle is preferably 0.5-3.5 cm. The gastroretentive drug delivery system preferably contains an isolating layer and/or waterproofing layer between the hollow vesicle and the layer containing drug.

Abstract: The present invention relates to novel compounds 2-(?-n-pentanonyl)benzoates, their preparation method, the pharmaceutical composition containing the same, and their use in preparing the medicament for preventing and treating cardio-cerebral ischemic disease, inhibiting thrombosis and alleviating the disturbance of cardio-cerebral circulation.